Karuna Therapeutics Inc logo

KRTX

Karuna Therapeutics Inc

$263.69

Earnings Summary

Revenue
$0Mn
Net Profits
$-58.22Mn
Net Profit Margins
-Inf%

Highlights

Revenue:

Karuna Therapeutics Inc’s revenue jumped NaN% since last year same period to $0Mn in the Q1 2022. On a quarterly growth basis, Karuna Therapeutics Inc has generated -100% fall in its revenue since last 3-months.

Net Profits:

Karuna Therapeutics Inc’s net profit fell -90.9% since last year same period to $-58.22Mn in the Q1 2022. On a quarterly growth basis, Karuna Therapeutics Inc has generated -108.22% fall in its net profits since last 3-months.

Net Profit Margins:

Karuna Therapeutics Inc’s net profit margin jumped NaN% since last year same period to -Inf% in the Q1 2022. On a quarterly growth basis, Karuna Therapeutics Inc has generated -Inf% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Karuna Therapeutics Inc post its latest quarter earnings

EPS Estimate Current Quarter
-2.09
EPS Estimate Current Year
-2.09

Highlights

EPS Estimate Current Quarter:

Karuna Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -2.09 - a 0.95% jump from last quarter’s estimates.

EPS Estimate Current Year:

Karuna Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -2.09.

Key Ratios

Key ratios of the Karuna Therapeutics Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-1.95
Return on Assets (ROA)
-0.25
Return on Equity (ROE)
-0.42
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Karuna Therapeutics Inc’s earning per share (EPS) fell -77.27% since last year same period to -1.95 in the Q1 2022. This indicates that the Karuna Therapeutics Inc has generated -77.27% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Karuna Therapeutics Inc’s return on assets (ROA) stands at -0.25.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Karuna Therapeutics Inc’s return on equity (ROE) stands at -0.42.

Dividend Per Share (DPS):

Karuna Therapeutics Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-05
-2.11
-1.95
7.58%

Company Information

Karuna Therapeutics is a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions.Karuna understand there is a need for differentiated and more effective treatments that can help patients navigate the challenges presented by these severe and disabling disorders. Utilizing itsextensive knowledge of neuroscience, the Company is harnessing the untapped potential of the brain in pursuit of novel pathways to develop medicines that make meaningful differences in peoples' lives.

Organisation
Karuna Therapeutics Inc
Employees
63
Industry
Health Technology